{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T23:10:41Z","timestamp":1792192241015,"version":"4.4.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,10,19]],"date-time":"2020-10-19T00:00:00Z","timestamp":1603065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,19]],"date-time":"2020-10-19T00:00:00Z","timestamp":1603065600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001826","name":"ZONMW","doi-asserted-by":"publisher","award":["543002006"],"award-info":[{"award-number":["543002006"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001826","name":"ZONMW","doi-asserted-by":"publisher","award":["854020002"],"award-info":[{"award-number":["854020002"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Community Genet"],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Screening for rare diseases first began more than 50\u00a0years ago with neonatal bloodspot screening (NBS) for phenylketonuria, and carrier screening for Tay-Sachs disease, sickle cell anaemia and \u03b2-thalassaemia. NBS\u2019s primary aim is health gain for children, while carrier screening enables autonomous reproductive choice. While screening can be beneficial, it also has the potential to cause harm and thus decisions are needed on whether a specific screening is worthwhile. These decisions are usually based on screening principles and criteria. Technological developments, both treatment driven and test driven, have led to expansions in neonatal screening and carrier screening. This article demonstrates how the dynamics and expansions in NBS and carrier screening have challenged four well-known screening criteria (treatment, test, target population and programme evaluation), and the decision-making based on them. We show that shifting perspectives on screening criteria for NBS as well as carrier screening lead to converging debates in these separate fields. For example, the child is traditionally considered to be the beneficiary in NBS, but the family and society can also benefit. Vice versa, carrier screening may be driven by disease prevention, rather than reproductive autonomy, raising cross-disciplinary questions regarding potential beneficiaries and which diseases to include. In addition, the stakeholders from these separate fields vary: Globally NBS is often governed as a public health programme while carrier screening is usually available via medical professionals. The article concludes with a call for an exchange of vision and knowledge among all stakeholders of both fields to attune the dynamics of screening.<\/jats:p>","DOI":"10.1007\/s12687-020-00488-y","type":"journal-article","created":{"date-parts":[[2020,10,19]],"date-time":"2020-10-19T05:02:48Z","timestamp":1603083768000},"page":"257-265","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":51,"title":["Neonatal and carrier screening for rare diseases: how innovation challenges screening criteria worldwide"],"prefix":"10.1007","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5397-5544","authenticated-orcid":false,"given":"Martina C.","family":"Cornel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6038-6289","authenticated-orcid":false,"given":"Tessel","family":"Rigter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7847-683X","authenticated-orcid":false,"given":"Marleen E.","family":"Jansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3531-0597","authenticated-orcid":false,"given":"Lidewij","family":"Henneman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,19]]},"reference":[{"key":"488_CR1","doi-asserted-by":"publisher","first-page":"e35","DOI":"10.1097\/AOG.0000000000001951","volume":"129","author":"ACOG Committee Opinion-690","year":"2017","unstructured":"ACOG Committee Opinion-690 (2017) Carrier screening in the age of genomic medicine. American College of Obstetricians and Gynecologists. Obstet Gynecol 129:e35\u2013e40","journal-title":"Obstet Gynecol"},{"key":"488_CR2","first-page":"240","volume":"27","author":"American Society of Human Genetics","year":"1975","unstructured":"American Society of Human Genetics (1975) Genetic counselling. Am J Hum Genet 27:240\u2013242","journal-title":"Am J Hum Genet"},{"key":"488_CR3","doi-asserted-by":"publisher","first-page":"317","DOI":"10.2471\/BLT.07.050112","volume":"86","author":"A Andermann","year":"2008","unstructured":"Andermann A, Blancquaert I, Beauchamp S, D\u00e9ry V (2008) Revisiting Wilson and Jungner in the genomic age: a review of screening criteria over the past 40 years. Bull World Health Organ 86:317\u2013319","journal-title":"Bull World Health Organ"},{"key":"488_CR4","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1258\/jhsrp.2009.009084","volume":"15","author":"A Andermann","year":"2010","unstructured":"Andermann A, Blancquaert I, D\u00e9ry V (2010) Genetic screening: a conceptual framework for programmes and policy-making. J Health Serv Res Policy 15:90\u201397","journal-title":"J Health Serv Res Policy"},{"key":"488_CR5","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/s41576-019-0134-2","volume":"20","author":"S Antonarakis","year":"2019","unstructured":"Antonarakis S (2019) Carrier screening for recessive disorders. Nat Rev Genet 20:549\u2013561","journal-title":"Nat Rev Genet"},{"key":"488_CR6","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.3389\/fimmu.2019.02438","volume":"10","author":"M Blom","year":"2019","unstructured":"Blom M, Schoenaker MHD, Hulst M, de Vries MC, Weemaes CMR, Willemsen MAAP, Henneman L, van der Burg M (2019) Dilemma of reporting incidental findings in newborn screening programs for SCID: parents\u2019 perspective on ataxia telangiectasia. Front Immunol 10:2438","journal-title":"Front Immunol"},{"key":"488_CR7","first-page":"429","volume":"105","author":"CM Blumenfeld","year":"1966","unstructured":"Blumenfeld CM, Wallace MJ, Anderson R (1966) Phenylketonuria-the Guthrie screening test-a method of quantitation, observations on reliability and suggestions for improvement. Calif Med 105:429\u2013434","journal-title":"Calif Med"},{"key":"488_CR8","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1002\/mgg3.463","volume":"6","author":"FK Boardman","year":"2018","unstructured":"Boardman FK, Hale R (2018) How do genetically disabled adults view selective reproduction? Impairment identity and genetic screening. Mol Genet Genom Med 6:941\u2013956","journal-title":"Mol Genet Genom Med"},{"key":"488_CR9","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1038\/ejhg.2010.13","volume":"18","author":"Y Bombard","year":"2010","unstructured":"Bombard Y, Miller FA, Hayeems RZ, Avard D, Knoppers BM (2010) Reconsidering reproductive benefit through newborn screening: a systematic review of guidelines on preconception, prenatal and newborn screening. Eur J Hum Genet 18:751\u2013760","journal-title":"Eur J Hum Genet"},{"key":"488_CR10","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1542\/peds.2013-1441","volume":"132","author":"JP Brosco","year":"2013","unstructured":"Brosco JP, Paul DB (2013) The political history of PKU: reflections on 50 years of newborn screening. Pediatrics. 132:987\u2013989. https:\/\/doi.org\/10.1542\/peds.2013-1441","journal-title":"Pediatrics."},{"key":"488_CR11","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1007\/s10545-012-9484-z","volume":"35","author":"P Burgard","year":"2012","unstructured":"Burgard P, Rupp K, Lindner M, Haege G, Rigter T, Weinreich SS, Loeber JG, Taruscio D, Vittozzi L, Cornel MC, Hoffmann GF (2012) Newborn screening programmes in Europe; arguments and efforts regarding harmonization. Part 2. From screening laboratory results to treatment, follow-up and quality assurance. J Inherit Metab Dis 35:613\u2013625","journal-title":"J Inherit Metab Dis"},{"key":"488_CR12","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1080\/14737159.2020.1690456","volume":"19","author":"J Cannon","year":"2019","unstructured":"Cannon J, Van Steijvoort E, Borry P, Chokoshvili D (2019) How does carrier status for recessive disorders influence reproductive decisions? A systematic review of the literature. Expert Rev Mol Diagn 19:1117\u20131129. https:\/\/doi.org\/10.1080\/14737159.2020.1690456","journal-title":"Expert Rev Mol Diagn"},{"key":"488_CR13","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1002\/pd.5109","volume":"38","author":"D Chokoshvili","year":"2018","unstructured":"Chokoshvili D, Vears D, Borry P (2018) Expanded carrier screening for monogenic disorders: where are we now? Prenat Diagn 38:59\u201366","journal-title":"Prenat Diagn"},{"key":"488_CR14","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1038\/ejhg.2010.90","volume":"18","author":"NE Cousens","year":"2010","unstructured":"Cousens NE, Gaff CL, Metcalfe SA, Delatycki MB (2010) Carrier screening for beta-thalassaemia: a review of international practice. Eur J Hum Genet 18:1077\u20131083. https:\/\/doi.org\/10.1038\/ejhg.2010.90","journal-title":"Eur J Hum Genet"},{"key":"488_CR15","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s12687-011-0074-9","volume":"3","author":"GM De Wert","year":"2012","unstructured":"De Wert GM, Dondorp WJ, Knoppers BM (2012) Preconception care and genetic risk: ethical issues. J Community Genet 3:221\u2013228","journal-title":"J Community Genet"},{"key":"488_CR16","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1002\/pd.5611","volume":"40","author":"MB Delatycki","year":"2020","unstructured":"Delatycki MB, Alkuraya F, Archibald A, Castellani C, Cornel M, Grody WW, Henneman L, Ioannides AS, Kirk E, Laing N, Lucassen A, Massie J, Schuurmans J, Thong MK, van Langen I, Zlotogora J (2020) International perspectives on the implementation of reproductive carrier screening. Prenat Diagn 40:301\u2013310","journal-title":"Prenat Diagn"},{"key":"488_CR17","doi-asserted-by":"publisher","unstructured":"Dondorp W, de Wert G, Bombard Y, Bianchi DW, Bergmann C, Borry P, Chitty LS, Fellmann F, Forzano F, Hall A, Henneman L, Howard HC, Lucassen A, Ormond K, Peterlin B, Radojkovic D, Rogowski W, Soller M, Tibben A, Tranebj\u00e6rg L, van El CG, Cornel MC; European Society of Human Genetics; American Society of Human Genetics (2015) Non-invasive prenatal testing for aneuploidy and beyond: challenges of responsible innovation in prenatal screening. Eur J Hum Genet 23:1438\u201350. https:\/\/doi.org\/10.1038\/ejhg.2015.57","DOI":"10.1038\/ejhg.2015.57"},{"key":"488_CR18","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1097\/AOG.0000000000000666","volume":"125","author":"JG Edwards","year":"2015","unstructured":"Edwards JG, Feldman G, Goldberg J, Gregg AR, Norton ME, Rose NC, Schneider A, Stoll K, Wapner R, Watson MS (2015) Expanded carrier screening in reproductive medicine-points to consider: a joint statement of the American College of Medical Genetics and Genomics, American College of Obstetricians and Gynecologists, National Society of Genetic Counselors, Perinatal Quality Foundation, and Society for Maternal-Fetal Medicine. Obstet Gynecol 125:653\u2013662","journal-title":"Obstet Gynecol"},{"key":"488_CR19","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1136\/jmg.37.2.135","volume":"37","author":"G Elwyn","year":"2000","unstructured":"Elwyn G, Gray J, Clarke A (2000) Shared decision making and non-directiveness in genetic counselling. J Med Genet 37:135\u2013138","journal-title":"J Med Genet"},{"key":"488_CR20","doi-asserted-by":"publisher","first-page":"15061","DOI":"10.1038\/nrdp.2015.61","volume":"1","author":"A Fischer","year":"2015","unstructured":"Fischer A, Notarangelo LD, Neven B, Cavazzana M, Puck JM (2015) Severe combined immunodeficiencies and related disorders. Nat Rev Dis Primers 1:15061","journal-title":"Nat Rev Dis Primers"},{"issue":"Suppl. 2","key":"488_CR21","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.1038\/sj.ejhg.5201113","volume":"11","author":"B Godard","year":"2003","unstructured":"Godard B, Ten Kate LP, Evers-Kiebooms G, Aym\u00e9 S (2003) Population genetic screening programmes: principles, techniques, practices, and policies. Eur J Hum Genet 11(Suppl. 2):S49\u2013S87","journal-title":"Eur J Hum Genet"},{"key":"488_CR22","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1136\/bmj.322.7295.1174","volume":"322","author":"V Goel","year":"2001","unstructured":"Goel V (2001) Appraising organised screening programmes for testing for genetic susceptibility to cancer. BMJ 322:1174\u20131178","journal-title":"BMJ"},{"key":"488_CR23","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1542\/peds.2005-0553","volume":"117","author":"SD Grosse","year":"2006","unstructured":"Grosse SD, Boyle CA, Kenneson A, Khoury MJ, Wilfond BS (2006) From public health emergency to public health service: the implications of evolving criteria for newborn screening panels. Pediatrics 117:923\u2013929","journal-title":"Pediatrics"},{"key":"488_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijns6010001","volume":"6","author":"PL Hall","year":"2020","unstructured":"Hall PL, Sanchez R, Hagar AF, Jerris SC, Wittenauer A, Wilcox WR (2020) Two-tiered newborn screening with post-analytical tools for Pompe disease and mucopolysaccharidosis type I results in performance improvement and future direction. Int J Neonatal Screen 6:1","journal-title":"Int J Neonatal Screen"},{"key":"488_CR25","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1001\/jama.2016.11139","volume":"316","author":"IS Haque","year":"2016","unstructured":"Haque IS, Lazarin GA, Kang HP, Evans EA, Goldberg JD, Wapner RJ (2016) Modeled fetal risk of genetic diseases identified by expanded carrier screening. JAMA 316:734\u2013742","journal-title":"JAMA"},{"key":"488_CR26","volume-title":"Genetic screening","author":"Health Council of the Netherlands","year":"1994","unstructured":"Health Council of the Netherlands (1994) Genetic screening. Health Council of the Netherlands, The Hague Publication no 1994\/22. Available from https:\/\/www.healthcouncil.nl\/documents\/advisory-reports\/1994\/12\/19\/genetic-screening Accessed 1 May 2020"},{"key":"488_CR27","volume-title":"Screening: between hope and hype","author":"Health Council of the Netherlands","year":"2008","unstructured":"Health Council of the Netherlands (2008) Screening: between hope and hype. Health Council of the Netherlands, The Hague Publication no. 2008\/05E: 54"},{"key":"488_CR28","volume-title":"Neonatal screening for spinal muscular atrophy","author":"Health Council of the Netherlands","year":"2019","unstructured":"Health Council of the Netherlands (2019) Neonatal screening for spinal muscular atrophy. Health Council of the Netherlands, The Hague Publication no 2019\/15 Available from: https:\/\/www.healthcouncil.nl\/documents\/advisory-reports\/2019\/07\/23\/neonatal-screening-for-spinal-muscular-atrophy Accessed 30 April 2020"},{"key":"488_CR29","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1038\/ejhg.2015.271","volume":"24","author":"L Henneman","year":"2016","unstructured":"Henneman L, Borry P, Chokoshvili D, Cornel MC, van El CG, Forzano F, Hall A, Howard HC, Janssens S, Kayserili H, Lakeman P, Lucassen A, Metcalfe SA, Vidmar L, de Wert G, Dondorp WJ, Peterlin B (2016) Responsible implementation of expanded carrier screening. Eur J Hum Genet 24:e1\u2013e12","journal-title":"Eur J Hum Genet"},{"key":"488_CR30","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1038\/ejhg.2014.289","volume":"23","author":"HC Howard","year":"2015","unstructured":"Howard HC, Knoppers BM, Cornel MC, Wright Clayton E, S\u00e9n\u00e9cal K, Borry P, European Society of Human Genetics; P3G International Paediatric Platform; Human Genome Organisation; and the PHG Foundation (2015) Whole-genome sequencing in newborn screening? A statement on the continued importance of targeted approaches in newborn screening programmes. Eur J Hum Genet 23:1593\u20131600. https:\/\/doi.org\/10.1038\/ejhg.2014.289","journal-title":"Eur J Hum Genet"},{"key":"488_CR31","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/ejhg.2016.126","volume":"25","author":"ME Jansen","year":"2017","unstructured":"Jansen ME, Metternick-Jones SC, Lister KJ (2017) International differences in the evaluation of conditions for newborn bloodspot screening: a review of scientific literature and policy documents. Eur J Hum Genet 25:10\u201316. https:\/\/doi.org\/10.1038\/ejhg.2016.126","journal-title":"Eur J Hum Genet"},{"key":"488_CR32","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1002\/hast.874","volume":"48","author":"J Johnston","year":"2018","unstructured":"Johnston J, Lantos JD, Goldenberg A, Chen F, Parens E, Koenig BA, NSIGHT Ethics and Policy Advisory Board (2018) Sequencing newborns: a call for nuanced use of genomic technologies. Hast Cent Rep 48:S2\u2013S6","journal-title":"Hast Cent Rep"},{"issue":"Suppl 3","key":"488_CR33","doi-asserted-by":"publisher","first-page":"S192","DOI":"10.1007\/PL00014401","volume":"159","author":"MM Kaback","year":"2000","unstructured":"Kaback MM (2000) Population-based genetic screening for reproductive counseling: the Tay-Sachs disease model. Eur J Pediatr 159(Suppl 3):S192\u2013S195","journal-title":"Eur J Pediatr"},{"key":"488_CR34","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1159\/000253122","volume":"13","author":"A-M Laberge","year":"2010","unstructured":"Laberge A-M, Watts C, Porter K, Burke W (2010) Assessing the potential success of cystic fibrosis carrier screening: lessons learned from Tay-Sachs disease and \u03b2-thalassemia. Public Health Genomics 13:310\u2013319","journal-title":"Public Health Genomics"},{"key":"488_CR35","doi-asserted-by":"publisher","first-page":"e114391","DOI":"10.1371\/journal.pone.0114391","volume":"9","author":"GA Lazarin","year":"2014","unstructured":"Lazarin GA, Hawthorne F, Collins NS, Platt EA, Evans EA, Haque IS (2014) Systematic classification of disease severity for evaluation of expanded carrier screening panels. PLoS One 9:e114391. https:\/\/doi.org\/10.1371\/journal.pone.0114391","journal-title":"PLoS One"},{"key":"488_CR36","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1038\/ejhg.2017.56","volume":"25","author":"A Mackie","year":"2017","unstructured":"Mackie A (2017) UK National Screening Committee Criteria: clarification of two misunderstandings. Eur J Hum Genet 25:791","journal-title":"Eur J Hum Genet"},{"key":"488_CR37","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","volume":"377","author":"JR Mendell","year":"2017","unstructured":"Mendell JR, Al-Zaidy S, Shell R, Arnold WD, Rodino-Klapac LR, Prior TW, Lowes L, Alfano L, Berry K, Church K, Kissel JT, Nagendran S, L\u2019Italien J, Sproule DM, Wells C, Cardenas JA, Heitzer MD, Kaspar A, Corcoran S, Braun L, Likhite S, Miranda C, Meyer K, Foust KD, Burghes AHM, Kaspar BK (2017) Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med 377:1713\u20131722. https:\/\/doi.org\/10.1056\/NEJMoa1706198","journal-title":"N Engl J Med"},{"key":"488_CR38","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s12687-019-00441-8","volume":"11","author":"B Modell","year":"2020","unstructured":"Modell B (2020) Haemoglobin disorders\u2014a point of entry for community genetics services in India? J Community Genet 11:7\u20139","journal-title":"J Community Genet"},{"key":"488_CR39","unstructured":"Nuffield Council on Bioethics (1993) Genetic screening. Ethical issues. Available from: https:\/\/www.nuffieldbioethics.org\/publications\/genetic-screening Accessed 3 April 2020"},{"key":"488_CR40","unstructured":"Public Health England (2014) The UK NSC recommendation on Tay Sachs disease screening in pregnancy (archived). Available from https:\/\/legacyscreening.phe.org.uk\/taysachs Accessed 13 April 2020"},{"key":"488_CR41","doi-asserted-by":"publisher","DOI":"10.1093\/acprof:oso\/9780199214495.001.0001","volume-title":"Screening: evidence and practice","author":"AE Raffle","year":"2007","unstructured":"Raffle AE, Gray JAM (2007) Screening: evidence and practice. Oxford University Press, Oxford"},{"key":"488_CR42","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s12687-012-0092-2","volume":"3","author":"H Ropers","year":"2012","unstructured":"Ropers H (2012) On the future of genetic risk assessment. J Community Genet 3:229\u2013236","journal-title":"J Community Genet"},{"key":"488_CR43","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.pediatrneurol.2017.08.012","volume":"77","author":"LF Ross","year":"2017","unstructured":"Ross LF, Clarke AJ (2017) A historical and current review of newborn screening for neuromuscular disorders from around the world: lessons for the United States. Pediatr Neurol 77:12\u201322. https:\/\/doi.org\/10.1016\/j.pediatrneurol.2017.08.012","journal-title":"Pediatr Neurol"},{"key":"488_CR44","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s12687-019-00410-1","volume":"11","author":"S Sinha","year":"2020","unstructured":"Sinha S, Seth T, Colah RB, Bittles AH (2020) Haemoglobinopathies in India: estimates of blood requirements and treatment costs for the decade 2017-2026. J Community Genet 11:39\u201345. https:\/\/doi.org\/10.1007\/s12687-019-00410-1","journal-title":"J Community Genet"},{"key":"488_CR45","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.jcf.2015.08.007","volume":"15","author":"P Stafler","year":"2016","unstructured":"Stafler P, Mei-Zahav M, Wilschanski M (2016) The impact of national population carrier screening program on cystic fibrosis birth rate and age at diagnosis: implications for newborn screening. J Cyst Fibros 15:460\u2013466. https:\/\/doi.org\/10.1016\/j.jcf.2015.08.007","journal-title":"J Cyst Fibros"},{"key":"488_CR46","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s12687-010-0007-z","volume":"1","author":"LP Ten Kate","year":"2010","unstructured":"Ten Kate LP, Al-Gazali L, Anand S, Bittles A, Cassiman JJ, Christianson A, Cornel MC, Hamamy H, K\u00e4\u00e4ri\u00e4inen H, Kristoffersson U, Marais D, Penchaszadeh VB, Rahman P, Schmidtke J (2010) Community genetics. Its definition 2010. J Community Genet 1:19\u201322","journal-title":"J Community Genet"},{"key":"488_CR47","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1053\/j.semperi.2015.03.002","volume":"39","author":"BL Therrell","year":"2015","unstructured":"Therrell BL, Padilla CD, Loeber JG, Kneisser I, Saadallah A, Borrajo GJ, Adams J (2015) Current status of newborn screening worldwide: 2015. Semin Perinatol 39:171\u2013187. https:\/\/doi.org\/10.1053\/j.semperi.2015.03.002","journal-title":"Semin Perinatol"},{"key":"488_CR48","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/ejhg.2016.125","volume":"25","author":"S Van der Hout","year":"2017","unstructured":"Van der Hout S, Holtkamp KC, Henneman L, de Wert G, Dondorp WJ (2017) Advantages of expanded universal carrier screening: what is at stake. Eur J Hum Genet 25:17\u201321","journal-title":"Eur J Hum Genet"},{"key":"488_CR49","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1111\/bioe.12555","volume":"33","author":"S Van der Hout","year":"2019","unstructured":"Van der Hout S, Dondorp W, de Wert G (2019) The aims of expanded universal carrier screening: autonomy, prevention, and responsible parenthood. Bioethics 33:568\u2013576","journal-title":"Bioethics"},{"key":"488_CR50","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s12687-011-0063-z","volume":"3","author":"CG Van El","year":"2012","unstructured":"Van El CG, Pieters T, Cornel MC (2012) Genetic screening and democracy: lessons from debating genetic screening criteria in the Netherlands. J Community Genet 3:79\u201389. https:\/\/doi.org\/10.1007\/s12687-011-0063-z","journal-title":"J Community Genet"},{"key":"488_CR51","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1377\/hlthaff.2017.1578","volume":"37","author":"BS Wilfond","year":"2018","unstructured":"Wilfond BS, Kauffman TL, Jarvik GP, Reiss JA, Richards CS, McMullen C, Gilmore M, Himes P, Kraft SA, Porter KM, Schneider JL, Punj S, Leo MC, Dickerson JF, Lynch FL, Clarke E, Rope AF, Lutz K, Goddard KAB (2018) Lessons learned from a study of genomics-based carrier screening for reproductive decision making. Health Aff (Millwood) 37:809\u2013816. https:\/\/doi.org\/10.1377\/hlthaff.2017.1578","journal-title":"Health Aff (Millwood)"},{"key":"488_CR52","volume-title":"Principles and practice of screening for disease","author":"JM Wilson","year":"1968","unstructured":"Wilson JM, Jungner YG (1968) Principles and practice of screening for disease. World Health Organization, Geneva Available at https:\/\/apps.who.int\/iris\/handle\/10665\/37650. Accessed 1 May 2020"},{"key":"488_CR53","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1002\/jimd.12030","volume":"42","author":"C Wilson","year":"2019","unstructured":"Wilson C, Knoll D, de Hora M, Kyle C, Glamuzina E, Webster D (2019) The decision to discontinue screening for carnitine uptake disorder in New Zealand. J Inherit Metab Dis 42:86\u201392. https:\/\/doi.org\/10.1002\/jimd.12030","journal-title":"J Inherit Metab Dis"}],"container-title":["Journal of Community Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12687-020-00488-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12687-020-00488-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12687-020-00488-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,19]],"date-time":"2021-10-19T07:54:38Z","timestamp":1634630078000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12687-020-00488-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,19]]},"references-count":53,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["488"],"URL":"https:\/\/doi.org\/10.1007\/s12687-020-00488-y","relation":{},"ISSN":["1868-310X","1868-6001"],"issn-type":[{"value":"1868-310X","type":"print"},{"value":"1868-6001","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,19]]},"assertion":[{"value":"5 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by the any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}